Home › Funds › Propel Bio Management, LLC › SLN
Propel Bio Management, LLC position in SLN
SILENCE THERAPEUTICS PLC · Health Care
Propel Bio Management, LLC reported holding 191,733 shares of SLN (SILENCE THERAPEUTICS PLC) in its Q2 2026 13F filing — a position valued at US$2.1M, representing 1.10% of its reported portfolio and ranking #25 among its reported holdings. Propel Bio Management, LLC first reported this position in Q2 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Propel Bio Management, LLC's SLN position evolved
Propel Bio Management, LLC first disclosed a stake in SLN in Q2 2026 at 191,733 shares (US$2.1M).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 191.73K | $2.11M | New |
About SLN and 13F data
SLN (SILENCE THERAPEUTICS PLC) is a Health Care company. 35 other funds we track also report a position in SLN — the largest reported positions include Siren, L.L.C. (US$36.4M), TCG Crossover Management, LLC (US$33.3M), Redmile Group, LLC (US$23.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding SLN
- Siren, L.L.C. 3.31M sh · $36.36M · Q2 2026
- TCG Crossover Management, LLC 3.03M sh · $33.31M · Q2 2026
- Redmile Group, LLC 2.16M sh · $23.77M · Q2 2026
- Nantahala Capital Management, LLC 1.35M sh · $14.79M · Q2 2026
- Nextech Invest Ltd. 952.40K sh · $10.46M · Q2 2026
- 5AM Venture Management, LLC 476.20K sh · $5.23M · Q2 2026
- GREAT POINT PARTNERS LLC 450.00K sh · $4.94M · Q2 2026
- Tetragon Partners GP Ltd 300.00K sh · $3.29M · Q2 2026
- Ishara Investments LP 55.35K sh · $2.43M · Q2 2026
- M28 Capital Management LP 101.20K sh · $1.11M · Q2 2026
More on Propel Bio Management, LLC
FAQ
How long has Propel Bio Management, LLC held SLN?
Propel Bio Management, LLC has disclosed SLN holdings in 1 of the last 1 reported quarters, going back to Q2 2026.
What is Propel Bio Management, LLC's current position in SLN?
As of Q2 2026, Propel Bio Management, LLC holds 191.73K shares of SLN (SILENCE THERAPEUTICS PLC), valued at $2.11M, representing 1.10% of its reported portfolio and ranking #25.
Has Propel Bio Management, LLC been buying or selling SLN?
In the latest 13F filing (Q2 2026), Propel Bio Management, LLC newly opened its position in SLN.
Which other funds hold SLN?
Other major institutional holders of SLN include Siren, L.L.C., TCG Crossover Management, LLC, Redmile Group, LLC, among 35 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.